Table 1.
Open in new tab

Baseline Clinical and Biochemical Characteristics

PCOS-dOB-gLCPPCOS-d vs OB-gPCOS-d vs LCOB-g vs LC
Age (years)10 ± 1 (n = 21)10 ± 1 (n = 29)10 ± 1 (n = 17)0.77
Breast Tanner Stage  a52% I38% I24% I0.005  b
48% II17% II35% II
45% III41% III
Pubic Hair Tanner Stage  a65% I38% I24% I0.11b
25% II41% II59% II
5% III21% III12% III
5% IV6% IV
BMI Percentile86.2 ± 15.897.7 ± 2.448.0 ± 20.1
BMI z score1.4 ± 0.72.2 ± 0.40.0 ± 0.6<0.0001<0.0001<0.0001<0.0001
Total T (ng/dL)10 ± 5 (n = 21)10 ± 6 (n = 29)9 ± 9 (n = 17)0.29
SHBG (nmol/L)46 ± 24 (n = 21)28 ± 17 (n = 29)72 ± 23 (n = 17)<0.00010.0020.004<0.0001
Bioavailable T (ng/dL)4 ± 3 (n = 21)5 ± 4 (n = 29)2 ± 3 (n = 17)0.0010.760.010.001
DHEAS  (ng/mL)625 ± 391 (n = 21)639 ± 403 (n = 29)515 ± 389 (n = 15)0.39
Androstenedione (ng/dL)22 ± 15 (n = 21)32 ± 27 (n = 29)22 ± 15 (n = 17)0.18
Estradiol  (pg/mL)13 ± 7 (n = 17)21 ± 16 (n = 18)13 ± 7 (n = 14)0.07
AMH  (ng/mL)2.2 ± 1.0 (n = 17)1.2 ± 0.8 (n = 29)3.6 ± 3.2 (n = 14)0.0070.0070.680.08
PCOS-dOB-gLCPPCOS-d vs OB-gPCOS-d vs LCOB-g vs LC
Age (years)10 ± 1 (n = 21)10 ± 1 (n = 29)10 ± 1 (n = 17)0.77
Breast Tanner Stage  a52% I38% I24% I0.005  b
48% II17% II35% II
45% III41% III
Pubic Hair Tanner Stage  a65% I38% I24% I0.11b
25% II41% II59% II
5% III21% III12% III
5% IV6% IV
BMI Percentile86.2 ± 15.897.7 ± 2.448.0 ± 20.1
BMI z score1.4 ± 0.72.2 ± 0.40.0 ± 0.6<0.0001<0.0001<0.0001<0.0001
Total T (ng/dL)10 ± 5 (n = 21)10 ± 6 (n = 29)9 ± 9 (n = 17)0.29
SHBG (nmol/L)46 ± 24 (n = 21)28 ± 17 (n = 29)72 ± 23 (n = 17)<0.00010.0020.004<0.0001
Bioavailable T (ng/dL)4 ± 3 (n = 21)5 ± 4 (n = 29)2 ± 3 (n = 17)0.0010.760.010.001
DHEAS  (ng/mL)625 ± 391 (n = 21)639 ± 403 (n = 29)515 ± 389 (n = 15)0.39
Androstenedione (ng/dL)22 ± 15 (n = 21)32 ± 27 (n = 29)22 ± 15 (n = 17)0.18
Estradiol  (pg/mL)13 ± 7 (n = 17)21 ± 16 (n = 18)13 ± 7 (n = 14)0.07
AMH  (ng/mL)2.2 ± 1.0 (n = 17)1.2 ± 0.8 (n = 29)3.6 ± 3.2 (n = 14)0.0070.0070.680.08

Data are mean ± standard deviation. P values listed from ANOVA unless otherwise noted. Statistical assessment for differences between the groups performed only on BMI z score. The bold values just indicate the P values below the significance threshold of 0.05.

Abbreviations: AMH, anti-Müllerian hormone; BMI, body mass index; DHEAS, dehydroepiandrosterone sulfate; LC, lean control; OB-g, girls with obesity; PCOS-d, daughters of mothers with polycystic ovary syndrome; SHBG, sex hormone–binding globulin; T, testosterone.

aPercentage of subjects included in each group are noted. bFisher exact test. BMI percentiles reported for descriptive purposes only.

Table 1.
Open in new tab

Baseline Clinical and Biochemical Characteristics

PCOS-dOB-gLCPPCOS-d vs OB-gPCOS-d vs LCOB-g vs LC
Age (years)10 ± 1 (n = 21)10 ± 1 (n = 29)10 ± 1 (n = 17)0.77
Breast Tanner Stage  a52% I38% I24% I0.005  b
48% II17% II35% II
45% III41% III
Pubic Hair Tanner Stage  a65% I38% I24% I0.11b
25% II41% II59% II
5% III21% III12% III
5% IV6% IV
BMI Percentile86.2 ± 15.897.7 ± 2.448.0 ± 20.1
BMI z score1.4 ± 0.72.2 ± 0.40.0 ± 0.6<0.0001<0.0001<0.0001<0.0001
Total T (ng/dL)10 ± 5 (n = 21)10 ± 6 (n = 29)9 ± 9 (n = 17)0.29
SHBG (nmol/L)46 ± 24 (n = 21)28 ± 17 (n = 29)72 ± 23 (n = 17)<0.00010.0020.004<0.0001
Bioavailable T (ng/dL)4 ± 3 (n = 21)5 ± 4 (n = 29)2 ± 3 (n = 17)0.0010.760.010.001
DHEAS  (ng/mL)625 ± 391 (n = 21)639 ± 403 (n = 29)515 ± 389 (n = 15)0.39
Androstenedione (ng/dL)22 ± 15 (n = 21)32 ± 27 (n = 29)22 ± 15 (n = 17)0.18
Estradiol  (pg/mL)13 ± 7 (n = 17)21 ± 16 (n = 18)13 ± 7 (n = 14)0.07
AMH  (ng/mL)2.2 ± 1.0 (n = 17)1.2 ± 0.8 (n = 29)3.6 ± 3.2 (n = 14)0.0070.0070.680.08
PCOS-dOB-gLCPPCOS-d vs OB-gPCOS-d vs LCOB-g vs LC
Age (years)10 ± 1 (n = 21)10 ± 1 (n = 29)10 ± 1 (n = 17)0.77
Breast Tanner Stage  a52% I38% I24% I0.005  b
48% II17% II35% II
45% III41% III
Pubic Hair Tanner Stage  a65% I38% I24% I0.11b
25% II41% II59% II
5% III21% III12% III
5% IV6% IV
BMI Percentile86.2 ± 15.897.7 ± 2.448.0 ± 20.1
BMI z score1.4 ± 0.72.2 ± 0.40.0 ± 0.6<0.0001<0.0001<0.0001<0.0001
Total T (ng/dL)10 ± 5 (n = 21)10 ± 6 (n = 29)9 ± 9 (n = 17)0.29
SHBG (nmol/L)46 ± 24 (n = 21)28 ± 17 (n = 29)72 ± 23 (n = 17)<0.00010.0020.004<0.0001
Bioavailable T (ng/dL)4 ± 3 (n = 21)5 ± 4 (n = 29)2 ± 3 (n = 17)0.0010.760.010.001
DHEAS  (ng/mL)625 ± 391 (n = 21)639 ± 403 (n = 29)515 ± 389 (n = 15)0.39
Androstenedione (ng/dL)22 ± 15 (n = 21)32 ± 27 (n = 29)22 ± 15 (n = 17)0.18
Estradiol  (pg/mL)13 ± 7 (n = 17)21 ± 16 (n = 18)13 ± 7 (n = 14)0.07
AMH  (ng/mL)2.2 ± 1.0 (n = 17)1.2 ± 0.8 (n = 29)3.6 ± 3.2 (n = 14)0.0070.0070.680.08

Data are mean ± standard deviation. P values listed from ANOVA unless otherwise noted. Statistical assessment for differences between the groups performed only on BMI z score. The bold values just indicate the P values below the significance threshold of 0.05.

Abbreviations: AMH, anti-Müllerian hormone; BMI, body mass index; DHEAS, dehydroepiandrosterone sulfate; LC, lean control; OB-g, girls with obesity; PCOS-d, daughters of mothers with polycystic ovary syndrome; SHBG, sex hormone–binding globulin; T, testosterone.

aPercentage of subjects included in each group are noted. bFisher exact test. BMI percentiles reported for descriptive purposes only.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close